Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Hákon Valur Dansson,Lena Stempfle,Hildur Egilsdóttir,Alexander Schliep,Erik Portelius,Kaj Blennow,Henrik Zetterberg,Fredrik D. Johansson,

DOI: https://doi.org/10.1186/s13195-021-00886-5

2021-09-06

Alzheimer's Research and Therapy

Abstract:Abstract Background In Alzheimer’s disease, amyloid- β (A β ) peptides aggregate in the lowering CSF amyloid levels - a key pathological hallmark of the disease. However, lowered CSF amyloid levels may also be present in cognitively unimpaired elderly individuals. Therefore, it is of great value to explain the variance in disease progression among patients with A β pathology. Methods A cohort of n =2293 participants, of whom n =749 were A β positive, was selected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database to study heterogeneity in disease progression for individuals with A β pathology. The analysis used baseline clinical variables including demographics, genetic markers, and neuropsychological data to predict how the cognitive ability and AD diagnosis of subjects progressed using statistical models and machine learning. Due to the relatively low prevalence of A β pathology, models fit only to A β -positive subjects were compared to models fit to an extended cohort including subjects without established A β pathology, adjusting for covariate differences between the cohorts. Results A β pathology status was determined based on the A β 42 /A β 40 ratio. The best predictive model of change in cognitive test scores for A β -positive subjects at the 2-year follow-up achieved an R 2 score of 0.388 while the best model predicting adverse changes in diagnosis achieved a weighted F 1 score of 0.791. A β -positive subjects declined faster on average than those without A β pathology, but the specific level of CSF A β was not predictive of progression rate. When predicting cognitive score change 4 years after baseline, the best model achieved an R 2 score of 0.325 and it was found that fitting models to the extended cohort improved performance. Moreover, using all clinical variables outperformed the best model based only on a suite of cognitive test scores which achieved an R 2 score of 0.228. Conclusion Our analysis shows that CSF levels of A β are not strong predictors of the rate of cognitive decline in A β -positive subjects when adjusting for other variables. Baseline assessments of cognitive function accounts for the majority of variance explained in the prediction of 2-year decline but is insufficient for achieving optimal results in longer-term predictions. Predicting changes both in cognitive test scores and in diagnosis provides multiple perspectives of the progression of potential AD subjects.